We help detect diseases earlier so you can start therapy sooner

Our screening algorithms are designed to detect early signs of disease while minimizing false positives. They are designed and developed the medical device standard and validated for the prospective performance.

Disease Screening

Transthyretin amyloid cardiomyopathy

Estimates the relative prevalence of ATTR-CM by comparing clinical features extracted from the electronic health records of individual patients against a reference population

SA.001

Cardiology
General internal medicine

Canada

IL-1 mediated autoinflammatory diseases

Estimates the relative prevalence of adult-onset Still's disease and other IL-1 mediated autoinflammatory diseases by comparing clinical features extracted from the electronic health records of individual patients against a reference population

SA.004

Rheumatology

Canada

Amyotrophic lateral sclerosis

Estimates the relative prevalence of ALS by comparing clinical features extracted from the electronic health records of individual patients against a reference population

SA.006

Neurology

Canada

Paroxysmal nocturnal hemoglobinuria

Estimates the relative prevalence of PNH by comparing clinical features extracted from the electronic health records of individual patients against a reference population

SA.012

Gastroenterology
General internal medicine
Nephrology
Urology

Canada

Clinical Guidelines

Dyslipidemia

Identifies patients eligible for more intensive lipid management according to the 2021 Canadian Cardiovascular Society Dyslipidemia Guidelines

GA.001

Cardiology
General internal medicine

Canada

Cardiometabolic antidiabetic agents

Identifies patients eligible for medical management with a GLP-1 receptor agonist or SGLT2 inhibitor according to the Canadian Cardiovascular Society Guidelines for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults

GA.002

Cardiology
General internal medicine

Canada

Cardiometabolic antidiabetic agents

Identifies patients eligible for medical management with a GLP-1 receptor agonist or SGLT2 inhibitor according to the Diabetes Canada 2024 Clinical Practice Guidelines

GA.003

General internal medicine
Primary care

Canada

Practice Assessment

Heart failure

Identifies patients eligible for more intensive lipid management according to the 2021 Canadian Cardiovascular Society Dyslipidemia Guidelines

OA.006

Cardiology
General internal medicine

Canada

Cardiometabolic antidiabetic agents

Identifies patients eligible for medical management with a GLP-1 receptor agonist or SGLT2 inhibitor according to the Canadian Cardiovascular Society Guidelines for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults

GA.002

Rheumatology

Canada

Cardiometabolic antidiabetic agents

Identifies patients eligible for medical management with a GLP-1 receptor agonist or SGLT2 inhibitor according to the Diabetes Canada 2024 Clinical Practice Guidelines

GA.003

Cardiology
Endocrinology
General internal medicine
Primary care

Canada

Our Science

Relevant Parameters

Our algorithms rely exclusively on relevant clinical parameters. We don't employ big data techniques to draw loose inferences from codes or claims or require structured data. Our machine learning tools are embedded in our data extraction platform rather than in our algorithms. They only operate unsupervised at thresholds that yield 100% accuracy. We manage uncertainty with technology-enabled abstraction by trained healthcare professionals.

This allows us to build tools that are unrivalled in their precision. It's why our ATTR-CM algorithm is driven by reported echo parameters like IVSD, E/E' and GLS, why our ALS algorithm can incorporate the presence of sharp waves on EMG in patients with clinical fasciculations and why our IL-1 mediated autoinflammatory diseases algorithm can account for fever periodicity in its calculations.

Explainable Predictions

Our reports clearly and transparently explain why patients may be suitable for follow-up investigations or referrals to specialty centres. The clinical parameters that drove our calculations are always reported alongside pertinent positives, pertinent negatives and other signs or symptoms necessary to complete the clinical picture.

Our mission is to empower physicians with better tools. Our reports reflect our best efforts to realize it.

Data Labs

We deploy our digital diagnostics exclusively at our clinical data labs because:

  • It allows us to control for variability in source data formats;

  • We can achieve greater reliability and accuracy than if we were to deploy our solutions locally; and

  • It makes life easier for our customers.

We go to great lengths to keep health information safe and secure including through the adoption of novel asymmetric de-identification and encryption techniques.

Explore our pipelineLearn how to order